Novartis' Exelon To Be Reviewed By Advisory Cmte. May 17
This article was originally published in The Pink Sheet Daily
Executive Summary
The company is seeking approval for rivastigmine tartrate for the treatment of mild to moderate dementia associated with Parkinson's disease.
You may also be interested in...
Exelon sNDA For Parkinson’s-Related Dementia Requires Just One Trial, Committee Says
FDA’s Peripheral & Central Nervous Systems Drugs Advisory Committee agrees that dementia associated with Parkinson’s disease qualifies as distinct from Alzheimer’s-type dementia.
Exelon sNDA For Parkinson’s-Related Dementia Requires Just One Trial, Committee Says
FDA’s Peripheral & Central Nervous Systems Drugs Advisory Committee agrees that dementia associated with Parkinson’s disease qualifies as distinct from Alzheimer’s-type dementia.
Exelon Panel To Debate Parkinson’s-Related Dementia As Distinct Condition
Novartis’ sNDA for the Alzheimer’s therapy is the first application for a Parkinson’s-related dementia indication.